Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

79 trials with published results (16%)

Research Maturity

371 completed trials (77% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.9%

9 terminated out of 479 trials

Success Rate

97.6%

+11.1% vs benchmark

Late-Stage Pipeline

7%

33 trials in Phase 3/4

Results Transparency

21%

79 of 371 completed with results

Key Signals

79 with results98% success

Data Visualizations

Phase Distribution

428Total
Not Applicable (44)
Early P 1 (8)
P 1 (328)
P 2 (15)
P 3 (3)
P 4 (30)

Trial Status

Completed371
Unknown56
Recruiting20
Withdrawn11
Terminated9
Not Yet Recruiting7

Trial Success Rate

97.6%

Benchmark: 86.5%

Based on 371 completed trials

Clinical Trials (479)

Showing 20 of 20 trials
NCT07422285Phase 1Recruiting

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT05041699Phase 1CompletedPrimary

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

NCT06500793Phase 1RecruitingPrimary

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT05539872Phase 2CompletedPrimary

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT04961593RecruitingPrimary

PK/PD of Caspofungin in Children Severe Infection

NCT07102095Phase 1Completed

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

NCT07312643Phase 1CompletedPrimary

Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

NCT06854783Phase 1CompletedPrimary

Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

NCT06665555Phase 1CompletedPrimary

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

NCT06480981Phase 1CompletedPrimary

Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers

NCT06426836Not ApplicableRecruitingPrimary

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

NCT02456974RecruitingPrimary

Antibiotic Dosing in Pediatric Intensive Care

NCT07285967Phase 1Not Yet Recruiting

A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

NCT06733675Phase 1Recruiting

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06921590Phase 1Active Not RecruitingPrimary

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

NCT05488678Phase 1CompletedPrimary

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

NCT05527834Phase 1CompletedPrimary

Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants

NCT06095895CompletedPrimary

Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment

NCT07202663Phase 1Recruiting

Study of BB-025, Alone and After BB-031, in Healthy Volunteers

NCT06752122Phase 1Recruiting

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

Scroll to load more

Research Network

Activity Timeline